Clinical Trial Update: Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 in adults with Ph+ chronic myeloid leukemia resistant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• PF-114

Snippet

Sponsor: Fusion Pharma LLC | Conditions: Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 1, Phase 2 | Status: UNKNOWN